Neuphoria Therapeutics (NEUP) Current Assets (2021 - 2026)

Neuphoria Therapeutics (NEUP) has reported Current Assets for 6 consecutive years, with $21.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Current Assets rose 26.73% year-over-year to $21.7 million in Q1 2026; TTM through Mar 2026 was $21.7 million, a 26.73% increase from a year earlier, with the FY2025 full-year figure at $15.0 million, up 14.0% from the prior year.
• Current Assets was $21.7 million for Q1 2026 at Neuphoria Therapeutics, down from $23.4 million in the prior quarter.
• Over five years, Current Assets peaked at $29.9 million in Q2 2022 and troughed at $4.4 million in Q4 2024.
• A 5-year average of $16.1 million and a median of $14.5 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 55.15% in 2023 and soared 431.69% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $29.9 million in 2022, then tumbled by 55.15% to $13.4 million in 2023, then tumbled by 67.25% to $4.4 million in 2024, then soared by 431.69% to $23.4 million in 2025, then dropped by 7.39% to $21.7 million in 2026.
• The last three Current Assets figures came in at $21.7 million (Q1 2026), $23.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.